Evidence map›Paper›PMID 40464685›Full record

ArticleNucleic acids research2025

Methyl-CODEC enables simultaneous methylation and duplex sequencing.

Ruolin Liu, Farzaneh Darbeheshti, Laurel Walsh, Rachel Li, Jin H Bae, Hayet Radia Zeggar, Azeet Narayan, Kan Xiong, G Mike Makrigiorgos, Viktor A Adalsteinsson

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Replication-coupled hemimethylation inFrontiers in microbiology · 2026
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ruolin LiuBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.ORCID 0000-0001-9059-6335
Farzaneh DarbeheshtiDana-Farber Cancer Institute, Boston, MA 02142, United States.ORCID 0000-0002-4957-9004
Laurel WalshBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.
Rachel LiBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.
Jin H BaeBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.ORCID 0000-0002-4059-5198
Hayet Radia ZeggarDana-Farber Cancer Institute, Boston, MA 02142, United States.
Azeet NarayanBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.
Kan XiongBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.ORCID 0000-0002-0639-5803
G Mike MakrigiorgosDana-Farber Cancer Institute, Boston, MA 02142, United States.ORCID 0000-0001-7598-2406
Viktor A AdalsteinssonBroad Institute of MIT and Harvard, Cambridge, MA 02215, United States.

Funding

Comprehensive minimal residual disease tracking in cancerR01CA221874 · NCI · DANA-FARBER CANCER INST · PI Viktor Adalsteinsson, G. Mike Makrigiorgos · 2018 to 2026
$2.5M
NCI NIH HHS 2R01CA221874-04NCI NIH HHS R01 CA221874
6 · The paper itself

Abstract

DNA mutations and methylation often contribute to disease development in a synergistic manner. While duplex sequencing is the most accurate method for detecting DNA mutations, it typically lacks the ability to simultaneously assess methylation or requires many reads. Here, we developed Methyl-CODEC to enable simultaneous methylation sequencing and duplex sequencing using single read pairs. To achieve this, Methyl-CODEC links an enzymatically deaminated sense strand to the reverse complement of the antisense strand, which is protected from conversion by using conversion-resistant dCTPs in the strand linking step. Methyl-CODEC shows high concordance with standard enzymatic or bisulfite-based whole genome methylation sequencing, while also uniquely preserving the original DNA sequence. We show that hydroxy-methyl-dCTP is superior in this regard relative to other conversion-resistant dCTPs. Methyl-CODEC improves genetic sequencing accuracy, enables better read alignment for next-generation sequencing, and distinguishes C > T mutations from unmethylated Cs. It also identifies rare mutations including those producing methylated Cs, which are enriched in CpG contexts. Methyl-CODEC opens new horizons for enhanced detection of biomarkers in cancer and molecular medicine.

Indexed as

DNA MethylationHigh-Throughput Nucleotide SequencingSequence Analysis, DNACpG IslandsHumansMutation

Identifiers

PMID40464685
PMCPMC12135180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.